0001104659-23-089935.txt : 20230810 0001104659-23-089935.hdr.sgml : 20230810 20230810184518 ACCESSION NUMBER: 0001104659-23-089935 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230810 FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Divis Gregory J CENTRAL INDEX KEY: 0001410677 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 231161053 MAIL ADDRESS: STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 FORMER NAME: FORMER CONFORMED NAME: DIVIS GREG J DATE OF NAME CHANGE: 20070824 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 tm2323474-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-08-10 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001410677 Divis Gregory J C/O AVADEL PHARMACEUTICALS PLC 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 IRELAND 1 1 0 0 Chief Executive Officer 0 ADSs 2023-08-10 4 P 0 10000 13.1997 A 159100 D The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.86 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. /s/ Jerad G. Seurer, Attorney-in-Fact 2023-08-10